JUMP REPORT

CareDx (CDNA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Tenet Healthcare’s (THC) third-quarter earnings gain from the Ambulatory segment and lower expenses.

General nephrologists show a growing interest in AlloSure with 11 abstracts and educational symposiums at the largest nephrology meetingSOUTH SAN FRANCISCO, Calif., Oct. 21, 2020 (GLOBE NEWSWIRE) — CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced a leading presence with AlloSure education at the American Society of Nephrology (ASN) annual conference from October 22 – 25, 2020. The ASN annual conference, otherwise known as Kidney Week, will be run virtually this year. Eleven clinical abstracts on AlloSure have been selected for presentation during the poster and publication sessions of the conference, indicating that general nephrologists have a growing interest in surveillance tools for transplant patient management. CareDx also provided a grant for the educational symposium Diagnostic Controversies in Transplantation: Of Biomarkers and Biopsies.CareDx will host an Exhibitor Spotlight titled AlloSure as a Tool for Surveillance of Renal Transplant Patients: Real-World Evidence and Clinical Utility. During the spotlight session, five nephrologists will discuss their experiences with AlloSure and how it has benefitted their practice and their patients. The speakers and topics will be: * Dr. Vasil Peev, Rush University: Clinical Utility of Kidney Transplant Surveillance with AlloSure * Dr. Sanjiv Anand, Intermountain Medical Center: Baseline Characteristics and Relative Change Value of AlloSure * Dr. Tarek Alhamad, Barnes-Jewish Hospital: AlloSure as a Predictor of Clinical Outcomes * Dr. Nicole Ali, NYU Langone Health: COVID-19 and Renal Transplantation: The NYU Experience * Dr. Adit Mahale, Metrolina Nephrology Associates: AlloSure Experience in the Community “I am looking forward to presenting real-world AlloSure surveillance data across 1000 patients from multiple centers. It is really positive to see confirmation of the validation data in a cohort of real-world transplant patients, as well as the associations with meaningful clinical outcomes,” said Dr. Tarek Alhamad, Associate Professor and Medical Director of Transplant Nephrology at Washington University School of Medicine.“ASN is a tremendous opportunity for the nephrology community to share their experiences and to talk about best practices in kidney care for patients. This conference allows us to update the general nephrologists on the work that CareDx is doing to further clinical practice in transplant patient management,” said Peter Maag, CEO of CareDx.About CareDx CareDx, Inc., headquartered in South San Francisco, California, is a leading precision medicine solutions company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey, and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.CONTACTS:CareDx, Inc. Sasha King Chief Marketing Officer 415-287-2393 sking@caredx.comInvestor Relations Greg Chodaczek 347-620-7010 investor@caredx.com

CMS believes AlloMap reimbursement process is clinically appropriate for heart transplant patientsSOUTH SAN FRANCISCO, Calif., Oct. 19, 2020 (GLOBE NEWSWIRE) — CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced today that the Centers for Medicare and Medicaid Services (CMS) recently issued a memo recommending continued coverage of AlloMap through local Medicare Administrative Contractors (MACs). AlloMap is widely adopted by physician providers in over 90% of transplant centers across the US, has been the standard of care and incorporated into guidelines by the International Society for Heart and Lung Transplantation (ISHLT) since 2010, and is covered by a CPT code which is reimbursed by Noridian, the local MAC in California.The recently issued CMS memo was in response to a request made by a pathologist in January 2013 to make a national coverage determination to non-cover AlloMap. The CMS memo acknowledges that since 2013 there have been multiple studies that have demonstrated the clinical utility of AlloMap, and concludes that continuing the current AlloMap reimbursement process by MACs is clinically appropriate and in the best interests of beneficiaries.   “AlloMap has stood the test the time and is now cemented as the standard of care, being part of ISHLT guidelines since 2010. We continue to generate new insights with AlloMap with a strong growing evidence base, and it is positive to see CMS evaluate this evidence and continue to support use of AlloMap,” said Jeffrey Teuteberg, MD, Stanford.“CareDx is appreciative of the thorough evidence reviews performed by CMS, which reaffirm the clinical utility of AlloMap, and supports the CMS proposal to continue the current reimbursement process through MACs. Our dedication to patients continues to provide relevant testing services that are well supported by clinical data,” said Reg Seeto, President and Chief Business Officer, CareDx.About CareDx CareDx, Inc., headquartered in South San Francisco, California, is a leading precision medicine solutions company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey, and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.CONTACTS:CareDx, Inc. Sasha King Chief Marketing Officer 415-287-2393 sking@caredx.comInvestor Relations Greg Chodaczek 347-620-7010 investor@caredx.com

Virtual events to highlight newest innovation and solutions for HLA labs during ASHI conferenceSOUTH SAN FRANCISCO, Calif., Oct. 19, 2020 (GLOBE NEWSWIRE) — CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, announced that it will share the latest data on CareDx products for HLA laboratories at the 46th annual meeting of The American Society for Histocompatibility and Immunogenetics (ASHI). ASHI will be hosted virtually from October 19th – 21st 2020.At ASHI 2020, CareDx will host a virtual symposium, a virtual happy hour, and several meet-the-expert sessions. The symposium titled “Changing the Paradigm of HLA Typing: More HLA, More than HLA” will be held on Tuesday, Oct 20th from 2 PM – 3 PM EDT. The program will highlight the experience from Dr. Rajalingam Raja, Ph.D., FRCPath., D(ABHI). He is the Director of the Immunogenetics and Transplantation Laboratory at UCSF and will share his experience using AlloSeq Tx17 as their primary HLA typing solution.Additionally, there will be one oral talk on AlloSeq Tx 17 and nine posters on CareDx offerings presented during ASHI:Presentation: Monday, October 19th, 2020, 3:00 – 4:30 PM EDT * Reduced PCR-induced errors from a hybrid capture-based NGS assay for HLA typing – Nicholas Brown, PhD, University of PennsylvaniaPoster Session: Tuesday, October 20th, 2020, 5:30 – 6:30 PM EDT * AlloSeq Tx Hybrid Capture Technique allows successful typing with poorly performing registry samples and difficult samples where PCR-based methodologies fail * Beyond HLA-NGS AlloSeq TX 8 novel hybrid capture approach for high throughput volunteer donor typing with expandable gene content including ABO * 96 Sample throughput HLA typing following targeted gene enrichment by hybrid capture * Quantitative application of hybrid capture for HLA typing: Confirmation of hemizygosity and potential for detection of LOH * Genetic risk factors in solid organ transplantation: Beyond classical human leukocyte antigen * Description of 14 new HLA-J alleles reveals four distinct lineages * The HLA-F, -G, -H haplotype on the 8.1 ancestral haplotype differs from non-8.1 haplotypes with a *01:01:01:01: Implications for disease association studies and unrelated hematopoietic stem cell transplant * 35 UNIQUE HLA-f, -G, -H Haplotypes and their relationships to HLA-A: HLA-A is insufficient as a marker for genomic matching in unrelated HSCT * AlloSeq HCT, an accurate, reproducible and sensitive NGS-based solution for chimerism monitoring“These unprecedented times shine a light on how important our work is within the HLA community,” said Maria P. Bettinotti, PhD, Assistant Professor of Medicine and Director, Immunogenetics Laboratory, Johns Hopkins School of Medicine. “I am glad that CareDx is leveraging this Virtual ASHI platform and engaging this community while offering collaborative and innovative talks during this conference.”“Each year ASHI allows us to update the HLA laboratory community on the work that CareDx is doing in the field of immunogenetics and transplant immunology,” said Peter Maag, CEO of CareDx. “This year, we will have some exciting presentations for the pre- and post-transplant audiences along with multiple opportunities for physicians to learn from one another and get valuable updates regarding best practices in patient care.”About CareDx CareDx, Inc., headquartered in South San Francisco, California, is a leading precision medicine solutions company focused on the discovery, development and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. CareDx offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey, and is the leading provider of genomics-based information for transplant patients. For more information, please visit: www.CareDx.com.CONTACTS:CareDx, Inc. Sasha King Chief Marketing Officer 415-287-2393 sking@caredx.comInvestor Relations Greg Chodaczek 347-620-7010 investor@caredx.com